MARKET

CHRS

CHRS

Coherus Bioscien
NASDAQ
2.390
-0.030
-1.24%
After Hours: 2.370 -0.02 -0.84% 18:34 03/28 EDT
OPEN
2.420
PREV CLOSE
2.420
HIGH
2.510
LOW
2.360
VOLUME
2.10M
TURNOVER
0
52 WEEK HIGH
8.65
52 WEEK LOW
1.430
MARKET CAP
269.39M
P/E (TTM)
-0.9460
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CHRS last week (0318-0322)?
Weekly Report · 4d ago
Coherus Biosciences: Dumping One Drug But Showing Promise With Another
Coherus Biosciences has sold Cimerli, a Lucentis biosimilar, to Sandoz for $170M. CHRS has a new drug and a developmental pipeline. The company's anti-IL-27 antibody, casdozokitug, shows promising results in hepatocellular carcinoma. I upgrade my rating from hold to buy for Coherus.
Seeking Alpha · 03/21 00:14
Coherus BioSciences Price Target Cut to $11.00/Share From $13.00 by HC Wainwright & Co.
Dow Jones · 03/20 11:28
Coherus BioSciences Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/20 11:28
HC Wainwright & Co. Maintains Buy on Coherus BioSciences, Lowers Price Target to $11
Benzinga · 03/20 11:19
Buy Rating on Coherus Biosciences: Balancing Divestiture with Promising Pipeline and Financial Growth
TipRanks · 03/20 10:16
Weekly Report: what happened at CHRS last week (0311-0315)?
Weekly Report · 03/18 10:03
Coherus Biosciences: Strong Q4 Performance and Strategic Moves Merit Outperform Rating
TipRanks · 03/15 05:36
More
About CHRS
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.

Webull offers Coherus Biosciences Inc stock information, including NASDAQ: CHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CHRS stock methods without spending real money on the virtual paper trading platform.